ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026
Developing improved inoculants through genome editing of diazotrophic bacteria for cereals: Is this the right time for Brazil?
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Microbial inoculants for grasses containing Azospirillum brasilense have been commercially available in Brazil for 15 years, achieving great success and being applied in more than one-third of the Brazilian maize fields. However, these inoculant technologies could be improved by applying modern genomic editing tools, leading to the development of remodelled strains with increased diazotrophic ability. The most successful example of this kind of inoculant development is provided by the Pivot Bio company in the United States, which has engineered diazotrophic Enterobacteriaceae used in products currently widespread throughout the US market. Pivot Bio had applied to commercialize inoculants with their remodeled strains in Brazil, with a positive evaluation from the National Technical Commission on Biosafety (CTNBio), indicating their legal feasibility. Brazilian researchers working in this field have several advantages that will enable them to move into the new generation of inoculants: we have tremendous microbial biodiversity, technically skilled teams, and a partially favorable regulatory framework. We should move towards these enhanced inoculants to capitalize on our advantages, develop a new, genuine Brazilian technology, and achieve yield increases, cost reductions, and improved sustainability in Brazilian agricultural fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.